What is the recommended Lantus (insulin glargine) dose, carb ratio, and correction scale for a Type 2 DM patient with HbA1C 11.9%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Insulin Regimen for Type 2 Diabetes with HbA1c 11.9%

For a patient with Type 2 diabetes with HbA1c of 11.9%, BMI 23, and weight 71.6 kg, the recommended Lantus starting dose is 14-15 units daily, with a carbohydrate ratio of 1:10 and a correction factor of 1 unit for every 50 mg/dL above target glucose. 1, 2

Initial Insulin Dosing

  • Lantus (insulin glargine) starting dose should be 0.2 units/kg or up to 10 units once daily for insulin-naïve patients with type 2 diabetes 1, 2
  • For this 71.6 kg patient with very poor glycemic control (HbA1c 11.9%), calculate: 71.6 kg × 0.2 units/kg = 14.3 units, rounded to 14-15 units of Lantus daily 2
  • Administer Lantus subcutaneously once daily at the same time every day, preferably into the abdominal area, thigh, or deltoid 2
  • With HbA1c >10%, basal insulin plus mealtime insulin is often the preferred initial regimen 1

Carbohydrate Ratio and Correction Scale

  • Initial carbohydrate ratio: Start with 1:10 (1 unit of rapid-acting insulin for every 10 grams of carbohydrate) 1
  • Correction factor: Begin with 1 unit of rapid-acting insulin for every 50 mg/dL above target blood glucose 1
  • Target pre-meal glucose: 90-130 mg/dL 1
  • Target post-meal glucose: <180 mg/dL 1

Titration Algorithm

  • Adjust Lantus dose by 2-4 units every 3-4 days until fasting blood glucose consistently reaches 90-130 mg/dL 1, 2
  • If severe hypoglycemia occurs or blood glucose falls below 70 mg/dL, reduce the Lantus dose by 10-20% 2
  • Equip patient with self-titration algorithm based on self-monitoring of blood glucose to improve glycemic control 1

Comprehensive Management Approach

  • With HbA1c 11.9%, this patient requires aggressive glycemic management to reduce risk of complications 1
  • Target HbA1c should be <7% given the patient's normal BMI and absence of information suggesting limited life expectancy or advanced complications 1
  • Continue metformin if already prescribed and not contraindicated 1
  • Monitor for hypoglycemia, especially at night, as this is less common with insulin glargine compared to NPH insulin but still a significant risk 3

Follow-up and Monitoring

  • Check HbA1c every 3 months until target is achieved 1
  • Assess for symptoms of hypoglycemia and hyperglycemia at each visit 2
  • If basal insulin has been titrated to acceptable fasting blood glucose but HbA1c remains above target, consider advancing to combination injectable therapy with mealtime insulin 1
  • Consider consulting with endocrinology if glycemic targets are not achieved despite appropriate insulin titration 1

Common Pitfalls to Avoid

  • Inadequate initial dosing: Starting with too low a dose in a patient with HbA1c 11.9% will delay improvement 4
  • Failure to adjust: Not titrating insulin doses frequently enough based on blood glucose patterns 1
  • Overlooking patient education: Ensure patient understands injection technique, hypoglycemia recognition and management 1
  • Ignoring comprehensive care: Remember to address cardiovascular risk factors and screen for complications 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.